Mesenchymal Stem Cell-Derived Extracellular Vesicles in Bone-Related Diseases: Intercellular Communication Messengers and Therapeutic Engineering Protagonists
Yanyi Wang,Juan Wen,Tong Lu,Wei Han,Kai Jiao,Huang Li
DOI: https://doi.org/10.2147/ijn.s441467
IF: 7.033
2024-04-06
International Journal of Nanomedicine
Abstract:Yanyi Wang, 1, 2, &ast Juan Wen, 1– 3, &ast Tong Lu, 1, 2 Wei Han, 2, 4 Kai Jiao, 5 Huang Li 1, 2 1 Department of Orthodontics, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, Nanjing, People's Republic of China; 2 Medical School of Nanjing University, Nanjing, People's Republic of China; 3 Centre for Orofacial Regeneration, Reconstruction and Rehabilitation (COR3), School of Dentistry, The University of Queensland, Brisbane, Queensland, 4006, Australia; 4 Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, Nanjing, People's Republic of China; 5 Department of Stomatology, Tangdu Hospital & State Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration & National Clinical Research Center for Oral Diseases & Shaanxi Key Laboratory of Stomatology, School of Stomatology, The Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Han, Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, 30 Central Road, Nanjing, 210008, People's Republic of China, Email Huang Li, Department of Orthodontics, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, 30 Central Road, Nanjing, 210008, People's Republic of China, Tel +86-25-83620173, Fax +86-25-83620200, Email Extracellular vesicles (EVs) can deliver various bioactive molecules among cells, making them promising diagnostic and therapeutic alternatives in diseases. Mesenchymal stem cell-derived EVs (MSC-EVs) have shown therapeutic potential similar to MSCs but with drawbacks such as lower yield, reduced biological activities, off-target effects, and shorter half-lives. Improving strategies utilizing biotechniques to pretreat MSCs and enhance the properties of released EVs, as well as modifying MSC-EVs to enhance targeting abilities and achieve controlled release, shows potential for overcoming application limitations and enhancing therapeutic effects in treating bone-related diseases. This review focuses on recent advances in functionalizing MSC-EVs to treat bone-related diseases. Firstly, we underscore the significance of MSC-EVs in facilitating crosstalk between cells within the skeletal environment. Secondly, we highlight strategies of functional-modified EVs for treating bone-related diseases. We explore the pretreatment of stem cells using various biotechniques to enhance the properties of resulting EVs, as well as diverse approaches to modify MSC-EVs for targeted delivery and controlled release. Finally, we address the challenges and opportunities for further research on MSC-EVs in bone-related diseases. Keywords: extracellular vesicles, mesenchymal stem cells, functional modification, bone-related diseases The skeletal system undergoes a continuous process of remodeling, which involves both formation and degradation of bone tissues. 1 Multiple types of cells contribute to the maintenance of bone homeostasis. When the balance between bone synthesis and absorption is disrupted by intrinsic or extrinsic stimuli, it can lead to the development and progression of various bone diseases and defects, including metabolic disorders, inflammation, degeneration, neoplasms, and others. 2,3 Various therapeutic strategies have been used in addressing different bone diseases, including physical therapy, medications, and surgical interventions. 4–6 Among these, pharmacological treatments have evolved significantly owing to advances in bone biology research. For conditions like osteoporosis and osteoarthritis, drugs such as glucosamine, estrogen replacements, and chondroitin sulfate are commonly prescribed. 4,7 However, delivering these drugs specifically to the affected bone tissue poses challenges when administered orally or via intravenous injection, largely due to bodily excretion processes and the complex nature of the diseased skeletal tissues. 8 Additionally, the potential toxic effects on other organs and adverse systemic reactions remain concerns. Due to the intrinsic regenerative and anti-inflammatory capacities, MSCs-based cell therapy has also been extensively studied for bone related diseases. However, this strategy is faced with risks associated with tumorigenesis, potential immune reactions and long-term adverse eff -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology